MDCX · Medicus Pharma Ltd. · Documents

$1.89 +0.02 (+0.96%) Play latest call Q3 2026 earnings call transcript

Market Cap

$3.60M

1.92M

Volume · Nov 9 61.9K Avg daily vol (21 sessions) 75.51K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $47.28M 10-K filed Mar 25, 2026 Quarterly report New FY2026 Q3 Net loss $15.18M 10-Q filed Nov 6, 2026 Earnings call New Q3 2026 earnings call Held Nov 9, 2026

2026

Nov 9

Earnings call

Q3 2026 earnings call AI summary on its way

Nov 6

Quarterly report 10-Q FY2026 Q3, ended Sep 30

CD228V prioritized amid substantial going-concern doubt

Medicus Pharma Ltd. made CD228V its principal development priority on September 8, 2026. It reported a $3,370,880 working capital deficit and substantial doubt about continuing as a going concern.

Net loss $15.18M Diluted EPS -$11.64

Read from the MD&A section

4 source passages

Medicus Pharma Ltd. (the "Company") is a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets. On September 8, 2026, the Company announced a strategic update to its development portfolio under which CD228V has become the Company's principal development priority. The Company had a working capital deficit of $3,370,880 as of September 30, 2026. This uncertainty, together with the Company's history of losses and its outstanding debt obligations, including debt that will become current by year-end 2026, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. Open the document at this passage

Nov 4

Current report 8-K

SkinJect combination proposed at $135 million pre-money enterprise valuation

Medicus Pharma Ltd.’s wholly-owned Skinject, Inc. entered a non-binding letter of intent with an undisclosed SPAC for a proposed combination valuing Skinject at $135 million pre-money enterprise value, with concurrent financing and Medicus seeking majority economic and voting ownership.

Regulation FD disclosure

3 source passages

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that, its wholly-owned subsidiary, Skinject, Inc. ("SkinJect"), has entered into a non-binding letter of intent ("LOI") with an undisclosed special purpose acquisition company ("SPAC") for a proposed business combination involving SkinJect ("Business Combination"). The LOI contemplates a $135 million pre-money enterprise valuation for SkinJect and concurrent equity financing to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential New Drug Application ("NDA"). The proposed transaction is intended to establish a separately listed company dedicated to SkinJect, with Medicus seeking to retain majority economic and voting ownership. Open the document at this passage

Oct 30

Proxy statement DEF 14A Meeting Dec 2, 2026

Proxy statement

Medicus Pharma Ltd. shareholders will vote December 2, 2026 on creating unlimited blank cheque Class A Preferred Shares, authorizing a common-share split of up to one (1) pre-split share for every fifty (50) post-split shares, and approving meeting adjournment.

Read from the first part of this long document

Oct 23

Current report 8-K Events of Oct 20

Delisting notice or listing transfer, Other events

Medicus Pharma Ltd. regained Nasdaq compliance with the $1.00 minimum bid price requirement on October 23, 2026, closing the matter after Nasdaq had determined on October 20, 2026 to delist its shares and warrants.

Oct 19

Proxy statement PRE 14A Meeting Dec 2, 2026

Proxy statement

Medicus Pharma Ltd. will seek shareholder approval on December 2, 2026 to create unlimited Class A blank cheque preferred shares, authorize a reverse share split up to 1 pre-split Common Share for every 50 post-split Common Shares, and approve meeting adjournment.

Read from the first part of this long document

Oct 16

Current report 8-K Events of Oct 12

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Medicus Pharma Ltd. effected a 1-for-50 share consolidation of its common shares on October 12, 2026, after its board approved the ratio on September 24, 2026; shares began trading on a post-consolidation basis on Nasdaq the same day.

Oct 7

Current report 8-K

Other events

Medicus Pharma Ltd. will effect a fifty-to-one common share consolidation effective October 12, 2026 to regain Nasdaq Capital Market minimum bid-price compliance; every 50 common shares will become one, and the ticker will remain MDCX.

Sep 14

Current report 8-K Events of Sep 11

Ended a material agreement AI summary on its way

Sep 11

Current report 8-K Events of Sep 4

Unregistered sale of equity AI summary on its way

Sep 3

Current report 8-K Events of Sep 2

Entered into a material agreement AI summary on its way

Aug 12

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way